Trial record 1 of 1 for:
Phase 2 Study of Zevalin (ibritumomab tiuxetan) versus Zevalin and motexafin gadolinium
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
This study has been terminated.
(Due to business reasons.)
Sponsor:
Spectrum Pharmaceuticals, Inc
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc
ClinicalTrials.gov Identifier:
NCT01549886
First received: March 6, 2012
Last updated: March 25, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Estimated Study Completion Date: | July 2016 |
| Estimated Primary Completion Date: | June 2014 (Final data collection date for primary outcome measure) |